Dyadic International Inc.

History

Year	Detail
1979	Dyadic International was founded as an industrial textiles company and has evolved into the life sciences market.
1990s	The company started a research and development project at its American research facilities to expose the C1 Cells to random UV and chemical mutagenesis to accelerate the production of the targeted cellulase enzyme.
1996	The company started commercializing the C1-produced enzymes for industrial textile manufacturing.
2006	Dyadic partnered with Scripps to further annotate and characterize the C1 genome, generating data and maximizing the utilization of the C1 protein production platform.
2009	Dyadic received acknowledgment from the U.S. Food and Drug Administration (FDA) that the cellulase enzyme preparation derived from a genetically modified strain of its patented and proprietary C1 organism is generally recognized as safe (GRAS) under the intended conditions of use.
2015	The company launched the C1 platform for the development of human and animal vaccines, monoclonal antibodies, and other types and classes of therapeutic proteins.
2018	Dyadic collaborated with the Israel Institute for Biological Research (IIBR) to combat emerging diseases and threats, a collaboration that was expanded in 2020 at the start of the COVID-19 pandemic.
2020	The Frederick National Laboratory selected Dyadic to engineer its patented and proprietary C1 cell lines to produce several COVID-19 vaccine candidates. The Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, will utilize these candidates.
2021	The company entered into a technology transfer and licensing agreement with South Africa’s Rubic Consortium, aiming to develop and commercialize vaccines for distribution throughout the African Continent.